{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CPI&page=5",
    "query": {
      "intervention": "CPI",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 101,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CPI&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=CPI&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T17:25:18.318Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06471673",
      "title": "A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Tumor",
        "Cancer of Breast",
        "Cancer of the Breast",
        "Malignant Tumor of Breast",
        "Tumors, Breast"
      ],
      "interventions": [
        {
          "name": "BC1 cell line",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bria-OTS regimen and CPI (tislelizumab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bria-OTS regimen and CPI (tislelizumab) expansion cohort",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BriaCell Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-05-29",
      "completion_date": "2025-10-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-26",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 1,
      "location_summary": "Santa Monica, California",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06471673"
    },
    {
      "nct_id": "NCT01963052",
      "title": "ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Urothelial Cancer"
      ],
      "interventions": [
        {
          "name": "AGS15E",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 93,
      "start_date": "2013-11-14",
      "completion_date": "2019-07-08",
      "has_results": false,
      "last_update_posted_date": "2024-11-01",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • New Haven, Connecticut • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01963052"
    },
    {
      "nct_id": "NCT07566052",
      "title": "A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Setidegrasib",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 356,
      "start_date": "2026-04-28",
      "completion_date": "2030-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-20",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 8,
      "location_summary": "Glendale, California • Los Angeles, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Edison",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07566052"
    },
    {
      "nct_id": "NCT02981303",
      "title": "Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Melanoma",
        "Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Imprime PGG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "HiberCell, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 64,
      "start_date": "2017-02-22",
      "completion_date": "2020-12-31",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 10,
      "location_summary": "Avondale, Arizona • Santa Monica, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Avondale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Athens",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02981303"
    },
    {
      "nct_id": "NCT04322643",
      "title": "Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        },
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2020-03-23",
      "completion_date": "2023-04-17",
      "has_results": true,
      "last_update_posted_date": "2025-02-25",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04322643"
    },
    {
      "nct_id": "NCT03370159",
      "title": "CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stage IIIB Non-Small Cell Lung Cancer AJCC v7",
        "Stage IV Non-Small Cell Lung Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "6,8-Bis(benzylthio)octanoic Acid",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-06",
      "completion_date": "2020-03-01",
      "has_results": false,
      "last_update_posted_date": "2018-08-01",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03370159"
    },
    {
      "nct_id": "NCT03868891",
      "title": "Exercises for Improving Soft Palate and Eustachian Tube Function in Children With Ear Tubes With or Without Cleft Palate",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cleft Palate",
        "Tube Disorders Eustachian",
        "Velopharyngeal Incompetence Due to Cleft Palate",
        "Velopharyngeal Insufficiency"
      ],
      "interventions": [
        {
          "name": "EMST150",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Noel Jabbour",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 11,
      "start_date": "2019-08-16",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2023-06-23",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03868891"
    },
    {
      "nct_id": "NCT02702869",
      "title": "Allied Cleft & Craniofacial Quality-Improvement and Research Network (ACCQUIREnet)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cleft Lip",
        "Cleft Palate",
        "Cleft Lip and Palate"
      ],
      "interventions": [
        {
          "name": "cleft lip repair",
          "type": "PROCEDURE"
        },
        {
          "name": "cleft palate repair",
          "type": "PROCEDURE"
        },
        {
          "name": "oronasal fistula repair",
          "type": "PROCEDURE"
        },
        {
          "name": "pharyngoplasty",
          "type": "PROCEDURE"
        },
        {
          "name": "gingivoperiosteoplasty",
          "type": "PROCEDURE"
        },
        {
          "name": "LeFort-1 maxillary repositioning",
          "type": "PROCEDURE"
        },
        {
          "name": "rhinoplasty",
          "type": "PROCEDURE"
        },
        {
          "name": "myringotomy and tympanostomy tube placement",
          "type": "PROCEDURE"
        },
        {
          "name": "speech therapy",
          "type": "OTHER"
        },
        {
          "name": "orthodontia",
          "type": "PROCEDURE"
        },
        {
          "name": "presurgical orthopedics",
          "type": "PROCEDURE"
        },
        {
          "name": "sound amplification for hearing",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Day",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "1 Day to 22 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2016-10",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 10,
      "location_summary": "Gainesville, Florida • Hollywood, Florida • Orlando, Florida + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Portland",
          "state": "Maine"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02702869"
    },
    {
      "nct_id": "NCT05533697",
      "title": "Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "mRNA-4359",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 361,
      "start_date": "2022-09-01",
      "completion_date": "2032-02-18",
      "has_results": false,
      "last_update_posted_date": "2026-07-14",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05533697"
    },
    {
      "nct_id": "NCT06939283",
      "title": "A Phase 1b/2 Multisite Dose-finding and Expansion Study of WTX-330 in Adult Patients With Selected Advanced or Metastatic Solid Tumors or Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "WTX-330",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Werewolf Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2025-04-21",
      "completion_date": "2026-04-23",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-21T17:25:18.318Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06939283"
    }
  ]
}